TORRENT POWER: CO SAYS PROJECTS OF 8.4 GW IN MAHARASHTRA, UTTAR PRADESH UNDER PLANNING STAGE CO SAYS TARGET TO INCREASE RENEWABLE PORTFOLIO TO 4.4 GW CO SAYS EVALUATING BROWNFIELD OPPORTUNITIES TO STRENGTHEN PRESENCE . #Financial #FinancialNews TORRENT POWER: CO SAYS PROJECTS OF 8.4 GW IN MAHARASHTRA, UTTAR PRADESH UNDER PLANNING STAGE CO SAYS TARGET TO INCREASE RENEWABLE PORTFOLIO TO 4.4 GW CO SAYS EVALUATING BROWNFIELD OPPORTUNITIES TO STRENGTHEN PRESENCE . #Financial #FinancialNews

Posted on by Raj Gaurav Rai

TORRENT POWER: CO SAYS PROJECTS OF 8.4 GW IN MAHARASHTRA, UTTAR PRADESH UNDER PLANNING STAGE CO SAYS TARGET TO INCREASE RENEWABLE PORTFOLIO TO 4.4 GW CO SAYS EVALUATING BROWNFIELD OPPORTUNITIES TO STRENGTHEN PRESENCE . #Financial #FinancialNews TORRENT POWER: CO SAYS PROJECTS OF 8.4 GW IN MAHARASHTRA, UTTAR PRADESH UNDER PLANNING STAGE CO SAYS TARGET TO INCREASE RENEWABLE PORTFOLIO TO 4.4 GW CO SAYS EVALUATING BROWNFIELD OPPORTUNITIES TO STRENGTHEN PRESENCE . #Financial #FinancialNews

Please follow and like us:

Related Posts

Ztech India IPO GMP The company’s shares are seeing good demand in the grey market before the opening of the IPO. The price band for the IPO has been fixed at Rs 104-110 per share. A total of 33.91 lakh fresh equity shares will be issued under the issue. #ipo #FinancialNews #StockMarket #Investment Ztech India IPO GMP The company’s shares are seeing good demand in the grey market before the opening of the IPO. The price band for the IPO has been fixed at Rs 104-110 per share. A total of 33.91 lakh fresh equity shares will be issued under the issue. #ipo #FinancialNews #StockMarket #Investment

Ztech India IPO GMP The company's shares are seeing good demand in the grey market before the opening of the IPO. The price band for […]

*MASSIVE SETBACK FOR ZYDUS LIFE* Exelixis Wins Patent Ruling Over MSN Labs’ Cabometyx Copies MSN WILL NOT BE ABLE TO LAUNCH DRUG ZYDUS WAS MSN PARTNER, BIG SETBACK *MASSIVE SETBACK FOR ZYDUS LIFE* Exelixis Wins Patent Ruling Over MSN Labs’ Cabometyx Copies MSN WILL NOT BE ABLE TO LAUNCH DRUG ZYDUS WAS MSN PARTNER, BIG SETBACK

*MASSIVE SETBACK FOR ZYDUS LIFE*Exelixis Wins Patent Ruling Over MSN Labs' Cabometyx Copies MSN WILL NOT BE ABLE TO LAUNCH DRUGZYDUS WAS MSN PARTNER, BIG […]

Exit mobile version